Variable |
HBP (n = 37) |
LBBAP (n = 40) |
P |
Therapy indication |
|
|
.48 |
ABT, n (%) |
24 (64.1) |
22 (55) |
|
CRT, n (%) |
13 (35.9) |
18 (45) |
|
Previous device, n (%) |
6 (15.4) |
4 (10%) |
.51 |
Deflectable sheath, n (%) |
7 (18.9) |
3 (7.5) |
.18 |
>1 de novo lead, n (%) |
24 (64.9) |
32 (80) |
.14 |
FT, min |
17 (11.5–29) |
10 (7.25–13.95) |
<.001 |
Bundle branch block, n (%) |
20 (54.1) |
22 (55) |
.93 |
Baseline QRS, ms |
143 ± 45 |
140 ± 37 |
.64 |
Paced QRS, ms |
117 ± 19 |
109 ± 8.2 |
<.05 |
QCI, % |
–13.5 ± 19.4 |
–16.2 ± 23.7 |
.6 |
Wide baseline QRS, % |
23 (62.2) |
25 (62.5) |
.97 |
Wide paced QRS, % |
17 (45.9) |
5 (12.5) |
.001 |
Threshold at implantation, V |
1.5 (0.75–2.1) |
0.5 (0.5–0.74) |
<.001 |
Threshold at 3 months, V |
1.75 (0.75–2.4) |
0.72 (0.5–0.75) |
<.001 |
R-wave detection at implantation, mV |
4 ± 3 |
9.8 ± 3.9 |
<.001 |
R-wave detection at 3 months, mV |
4.9 ± 2.9 |
13.5 ± 4.5 |
<.001 |
Impedance at implantation, Ω |
538 ± 127 |
670 ± 94 |
<.001 |
Impedance at 3 months, Ω |
437 ± 104 |
560 ± 135 |
<.001 |